Checkpoint Therapeutics, Inc. (CKPT)

Market Cap	356.83M
Revenue (ttm)	41,000 -39.7%
Net Income	-56.51M
EPS	-1.22
Shares Out	83.76M
PE Ratio	n/a
Forward PE	8.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,666,849
Open	4.240
Previous Close	n/a
Day's Range	4.230 - 4.280
52-Week Range	1.800 - 4.500
Beta	1.18
Analysts	Buy
Price Target	4.33 (+1.64%)
Earnings Date	May 13, 2025

About CKPT

Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company’s lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It also developing Olafertini...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2017
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: CKPT
• Website: https://checkpointtx.com

Financial Performance

In 2024, Checkpoint Therapeutics's revenue was $41,000, a decrease of -60.19% compared to the previous year's $103,000. Losses were -$56.24 million, 8.47% more than in 2023.

Analyst Summary

According to 3 analysts, the average rating for CKPT stock is "Buy." The 12-month stock price target is $4.33, which is an increase of 1.64% from the latest price.

Price Target

$4.33

(1.64% upside)

Analyst Consensus: Buy